Immunic Inc is progressing its Phase 3 clinical trials for vidofludimus calcium, a drug candidate for relapsing multiple sclerosis (RMS), with topline data expected by the end of 2026. The company completed a $200 million private financing to fund operations through trial completion and potential commercial launch preparations. Immunic also plans to start a Phase 3 trial for primary progressive multiple sclerosis (PPMS) later this year, aiming for a New Drug Application submission in mid-2027 and potential approval in 2028. The drug combines neuroprotective and anti-inflammatory effects, showing promise in earlier trials and targeting a global MS market projected to exceed $30 billion by the early 2030s.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
